A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE)

Kim, Judy E.; Glassman, Adam R.; Josic, Kristin; Melia, Michele; Aiello, Lloyd Paul; Baker, Carl W.; Eells, Janis T.; Jampol, Lee M.; Kern, Timothy S.; Marcus, Dennis M.; Martín, Daniel; Salehi-Had, Hani; Shah, Sandeep N.; Stockdale, Cynthia R.; Sun, Jennifer K.

doi:10.1016/j.oret.2021.10.003

Cited by 27 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The parameters of irradiation used have varied widely, with the variation in the energy density ranging from 0.1 to 25 J/cm 2 , the variation in the irradiance ranging between 8 and 200 mW/cm 2 , and an irradiation duration anywhere between 80 and 250 s ( Table 2 ). However, several studies have reported that PBM plays a negative role in the treatment of progressed AMD, especially accompanied by DME with good visual eyesight [ 32 , 33 , 34 ] ( Table 3 ). Therefore, the progressive stage of retinal diseases is another factor that should be considered when adopting PBM to achieve the best clinical effects.…”

Section: Parameters Of Light Irradiationmentioning

confidence: 99%

Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases

et al. 2022

View full text Add to dashboard Cite

Photobiomodulation (PBM) refers to the beneficial effect produced from low-energy light irradiation on target cells or tissues. Increasing evidence in the literature suggests that PBM plays a positive role in the treatment of retinal diseases. However, there is great variation in the light sources and illumination parameters used in different studies, resulting in significantly different conclusions regarding PBM’s therapeutic effects. In addition, the mechanism by which PBM improves retinal function has not been fully elucidated. In this study, we conducted a narrative review of the published literature on PBM for treating retinal diseases and summarized the key illumination parameters used in PBM. Furthermore, we explored the potential molecular mechanisms of PBM at the retinal cellular level with the goal of providing evidence for the improved utilization of PBM in the treatment of retinal diseases.

show abstract

Section: Parameters Of Light Irradiationmentioning

confidence: 99%

Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…PBM treatment showed promise for improving patients with diabetic macular edema, with a post-treatment reduction in retinal thickness [94,95]. Kim and colleagues [96] conducted a randomized trial of PBM for center-involved diabetic macular edema (CI-DME) with good visual acuity. They concluded that 670nm light-emitting PBM as given in that study, although safe and well-tolerated, was not found to be effective for the treatment of CI-DME in eyes with good vision.…”

Section: Ophthalmological Applications Of Pbmmentioning

confidence: 99%

Photobiomodulation therapy in ophthalmology

Zadorozhnyy¹,

Korol²,

Nasinnyk³

et al. 2022

Oftalmol Zh

View full text Add to dashboard Cite

SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine) Photobiomodulation (PBM) therapy is a form of light therapy that utilizes non-ionizing forms of light sources in the far-red to near-infrared spectrum to produce non-thermal photochemical reactions in different biological structures. The paper reviews the experience of implementing (a) PBM in different fields of medicine (e.g., ophthalmology) and (b) the known mechanisms of PBM-induced effects on cells and tissues.

show abstract

“…8,19,20 Conversely, subvisible photochemical light-exposure procedures (photobiomodulation) use retinal irradiances lower than PDT. 24 Photo biomodulation therapy (PBT) is a non-thermal retinal light therapy that uses longer wavelength visible light or near-infrared radiation to produce photochemical reactions in endogenous retinal chromophores rather than PDT's intravenously-administered exogenous retinal photosensitizers including vertepor n. [24][25][26] PBT was ineffective for center-involving diabetic macular edema in a phase 2 randomized clinical trial, 27 but a pilot PBT study for non-neovascular age-related macular degeneration (AMD) 24,26,28 produced promising results. This latter study, recent vertepor n shortages, the widespread availability of PDT laser systems and our desire to decrease PDT's potential adverse effects prompted us to determine whether standard PDT full-uence 693 nm red laser light was useful for managing cCSC without vertepor n. We refer to this treatment as "no-dose PDT," consistent with terminology used in other PDT laser equipment procedures.…”

Section: Introductionmentioning

confidence: 99%

No-Dose Photodynamic Therapy Against half-dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy

Servillo

Sacconi

Zucchiatti

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective To describe the effects of no-dose full fluence photodynamic therapy without verteporfin (no-dose PDT) and to compare no-dose PDT with half-dose verteporfin full-fluence photodynamic therapy (HDFF PDT) for managing chronic central serous chorioretinopathy (cCSC). Methods This retrospective study evaluated 11 patients with chronic recurrent CSC treated with no-dose PDT between January 2019 and March 2022. Most of these patients were also treated with half-dose full-fluence PDT (HDFF PDT) a minimum of 3- months before and were considered as control group. We described the changes of best-corrected visual acuity (BCVA), maximum subretinal fluid (mSRF), foveal subretinal fluid (fSRF) and choroidal thickness (CT) 8 ± 2 weeks after no-dose PDT, and we compared BVCA, mSRF, fSRF and CT of no-dose PDT with those of the of same patients previously treated with HDFF PDT. Results Fifteen eyes of 11 patients (10 males, mean age 54 ± 12 years) received no-dose PDT; among these, 10 eyes of 8 patients (7 males, mean age 53 ± 12 years) received also HDFF PDT. Three eyes showed complete resolution of fSRF after no-dose PDT. No significant differences were disclosed between treatment with and without verteporfin comparing BCVA, mSRF, fSRF, and CT at the baseline and 8 ± 2 weeks from the treatment (p > 0.05 in all analyses). Conclusion BVCA and CT significantly improved after no-dose PDT. Short-term functional and anatomical treatment outcomes for cCSC were similar for HDFF PDT and no-dose PDT. We hypothesize that the potential benefits of no-dose PDT may arise thermal elevation triggers and enhances photochemical activities by endogenous fluorophores that activates a biochemical cascade response that rescues / replaces sick, dysfunctional RPE cells. Results of this study suggest the potential value of a prospective clinical trial to evaluate no-dose PDT for managing cCSC, especially when verteporfin is contraindicated or unavailable.

show abstract

A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE)

Cited by 27 publications

References 11 publications

Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases

Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases

Photobiomodulation therapy in ophthalmology

No-Dose Photodynamic Therapy Against half-dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy

Contact Info

Product

Resources

About